Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2014

View Archived Issues

Celgene acquires late-stage product for Crohn's disease

IO-125 supramolecular oxaliplatin analogue shows improved anticancer efficacy

Fluorinov compounds show activity against pain and epilepsy

Genentech LDH-A inhibitor targets glycolysis in tumors

AbbVie presents A-366, an inhibitor of G9a/GLP

Merck & Co. discloses new MAPK inhibitors for cancer

Janssen Biotech patents novel anti-TLR3 antibodies

Japanese researchers prepare new nACh receptor agonists for pruritus

Vernalis reports data from a phase Ib/II study of V-81444

Hyperion Therapeutics to acquire Andromeda Biotech

Amgen reviews milestone progress of first quarter 2014

PAR-1 antagonist F-16357 dose-dependently inhibits bladder contraction

MiR-296 presented as a prognostic and predictive molecular biomarker for laryngeal carcinoma

Chugai Pharmaceutical updates progress of first quarter 2014

Teva and Takeda sign agreement for rasagiline in Japan

Daiichi Sankyo licenses Agendia biomarker technology for cancer drug development

EMA approves canagliflozin and metformin combination

Boehringer Ingelheim's antithrombotic receives positive opinion from the EMA

FDA grants fast track designation to Sativex

EMA committee recommends approval of Mekinist

TB Alliance advancing PaMZ drug regimen for TB into phase III testing

Investigator-sponsored trial to study bavituximab and ipilimumab in advanced melanoma

Merck KGaA patent describes novel PARP/TANK inhibitors

FDA notes deficiencies at active ingredient supplier for Pozen's PA-8140, PA-32540